Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs.

Animals Antineoplastic Agents / administration & dosage Clinical Trials as Topic Drug Delivery Systems Drug Resistance, Neoplasm Exosomes / physiology Humans Immunotherapy Neoplasms / drug therapy Pharmaceutical Vehicles
Extracellular vesicles Nanocarriers Tangential flow filtration Tumor-derived exosome Tumor-microenvironment

Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
28 08 2020
Historique:
received: 01 03 2020
revised: 21 04 2020
accepted: 04 05 2020
pubmed: 23 5 2020
medline: 28 1 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Exosomes are small membranous vesicles implicated in intercellular signalling. Through their uncanny ability to carry and deliver donor cellular cargo (biomolecules) to target cells, they exert a profound effect on the regular functioning of healthy cells and play a significant role in pathogenesis and progression of several diseases, including cancer. The composition and number of endogenously circulating exosomes frequently vary, which is often reflective of the pathophysiological status of the cell. Applicability of exosomes derived from normal cells as a drug carrier with or without modifying their intraluminal and surface components are generally tested. Conversely, exosomes also are reported to contribute to resistance towards several anti-cancer therapies. Therefore, it is necessary to carefully evaluate the role of exosomes in cancer progression, resistance and the potential use of exosomes as a delivery vehicle of cancer therapeutics. In this review, we summarize the recent advancements in the exploitation of exosomes as a drug delivery vehicle. We also discuss the role of exosomes in conferring resistance to anti-cancer therapeutics. While this review is focused on cancer, the exosome-based drug delivery and resistance is also applicable to other human diseases.

Identifiants

DOI: 10.1016/j.canlet.2020.05.004 PMID: 32439419 PMC: PMC7327711
pubmed: 32439419
pii: S0304-3835(20)30232-9
doi: 10.1016/j.canlet.2020.05.004
pmc: PMC7327711
mid: NIHMS1599042
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Pharmaceutical Vehicles 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-28

Subventions

Organisme : NCI NIH HHS
ID : R01 CA167516
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA225520
Pays : United States
Organisme : BLRD VA
ID : I01 BX003420
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103639
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233201
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report no conflict of interest in this work.

Références

JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669940
Trends Cancer. 2020 Jan;6(1):20-30
pubmed: 31952777
Molecules. 2018 Apr 04;23(4):
pubmed: 29617321
Nanoscale. 2020 Jan 2;12(2):877-887
pubmed: 31833519
Nucleic Acids Res. 2019 Jan 8;47(D1):D516-D519
pubmed: 30395310
Microb Pathog. 2017 Sep;110:1-6
pubmed: 28634130
Mol Oncol. 2020 Mar;14(3):539-555
pubmed: 31901148
Cancer Lett. 2019 Sep 10;459:122-134
pubmed: 31173853
BMC Cancer. 2013 Sep 17;13:421
pubmed: 24044575
Biotechnol J. 2020 Jan;15(1):e1900163
pubmed: 31595685
Clin Cancer Res. 2020 May 1;26(9):2216-2230
pubmed: 32019860
J Adv Res. 2018 Jun 25;15:1-18
pubmed: 30581608
Int J Pharm. 2020 Jan 5;573:118802
pubmed: 31715354
J Transl Med. 2005 Feb 21;3(1):9
pubmed: 15723705
Cancer Med. 2019 Oct;8(13):6082-6094
pubmed: 31436393
Clin Cancer Res. 2016 Jan 15;22(2):395-404
pubmed: 26369630
Nanoscale. 2019 Mar 21;11(12):5377-5394
pubmed: 30849160
Sci Rep. 2019 Jan 24;9(1):663
pubmed: 30679544
Pol Merkur Lekarski. 2018 May 25;44(263):253-257
pubmed: 29813044
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul;12(4):e1621
pubmed: 32131140
Biochem Biophys Res Commun. 2016 Mar 25;472(1):53-9
pubmed: 26902116
PLoS One. 2012;7(12):e50999
pubmed: 23251413
Oncogene. 2017 Aug 24;36(34):4929-4942
pubmed: 28436951
Nano Lett. 2019 Jan 9;19(1):19-28
pubmed: 30517011
J Transl Med. 2020 Jan 8;18(1):12
pubmed: 31915008
Oncotarget. 2017 Oct 10;8(70):114722-114735
pubmed: 29383115
Cancer Res. 2019 Jul 15;79(14):3608-3621
pubmed: 31118200
Cytokine Growth Factor Rev. 2020 Feb;51:27-39
pubmed: 31917095
Front Oncol. 2019 Sep 06;9:869
pubmed: 31555599
Anticancer Res. 2019 Dec;39(12):6701-6709
pubmed: 31810935
Int J Stem Cells. 2020 Mar 30;13(1):13-23
pubmed: 31887849
Sci Rep. 2019 Mar 29;9(1):5335
pubmed: 30926864
Angew Chem Int Ed Engl. 2020 Jan 27;59(5):2018-2022
pubmed: 31746532
Apoptosis. 2011 Jan;16(1):1-12
pubmed: 20717727
Sci Rep. 2018 Aug 17;8(1):12377
pubmed: 30120298
Mol Med Rep. 2019 Jul;20(1):323-331
pubmed: 31115533
EBioMedicine. 2019 Apr;42:238-251
pubmed: 30917935
Int J Nanomedicine. 2019 Jan 11;14:531-541
pubmed: 30666112
J Extracell Vesicles. 2013 Jun 18;2:
pubmed: 24009892
J Control Release. 2013 Nov 28;172(1):229-238
pubmed: 23994516
Nanomedicine. 2019 Aug;20:102014
pubmed: 31152797
Sci Rep. 2018 Mar 1;8(1):3853
pubmed: 29497081
PLoS One. 2014 Feb 06;9(2):e88193
pubmed: 24516610
ACS Nano. 2018 Sep 25;12(9):9568-9577
pubmed: 30130093
Nat Commun. 2017 Sep 20;8(1):626
pubmed: 28931823
Cell Mol Bioeng. 2016 Sep;9(3):315-324
pubmed: 27800035
Front Biosci (Landmark Ed). 2013 Jan 01;18:58-79
pubmed: 23276909
Int J Cancer. 2020 Mar 15;146(6):1700-1716
pubmed: 31381140
Cells. 2019 Apr 03;8(4):
pubmed: 30987213
Braz J Med Biol Res. 2017 Nov 13;51(1):e6472
pubmed: 29160412
J Ovarian Res. 2016 Oct 18;9(1):65
pubmed: 27756418
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Nat Biomed Eng. 2020 Jan;4(1):69-83
pubmed: 31844155
Mol Cancer. 2020 Feb 5;19(1):26
pubmed: 32020881
Oncogene. 2020 Feb;39(7):1600-1616
pubmed: 31700155
Cell Signal. 2019 Nov;63:109385
pubmed: 31394194
Clin Pharmacol Ther. 2011 Apr;89(4):491-502
pubmed: 21368752
Cancers (Basel). 2019 Jun 09;11(6):
pubmed: 31181850
J Control Release. 2017 Nov 28;266:8-16
pubmed: 28916446
Clin Transl Oncol. 2020 Jul;22(7):1105-1116
pubmed: 31728833
Med Sci Monit. 2019 Sep 25;25:7209-7217
pubmed: 31553714
Int J Pharm. 2018 Dec 20;553(1-2):1-7
pubmed: 30316791
Eur J Pharm Biopharm. 2019 Dec;145:27-34
pubmed: 31629787
Nat Biotechnol. 2017 Mar;35(3):222-229
pubmed: 28244992
ACS Nano. 2017 Nov 28;11(11):10712-10723
pubmed: 29090896
Mol Ther. 2019 Nov 6;27(11):1939-1949
pubmed: 31402274
Int J Oncol. 2018 Sep;53(3):1013-1026
pubmed: 30015837
Am J Physiol Lung Cell Mol Physiol. 2017 Jan 1;312(1):L110-L121
pubmed: 27881406
Biochem Biophys Rep. 2018 May 02;14:104-113
pubmed: 29872742
Oncoimmunology. 2015 Aug 12;5(4):e1071008
pubmed: 27141373
Int J Biol Sci. 2020 Jan 14;16(4):633-643
pubmed: 32025211
ACS Nano. 2013 Sep 24;7(9):7698-710
pubmed: 24004438
Cancers (Basel). 2019 Oct 14;11(10):
pubmed: 31615145
Mol Cancer. 2019 Oct 23;18(1):146
pubmed: 31647023
Adv Exp Med Biol. 2017;998:255-269
pubmed: 28936745
J Biomed Nanotechnol. 2019 Nov 1;15(11):2202-2208
pubmed: 31847934
Tissue Eng Part C Methods. 2012 Jan;18(1):54-61
pubmed: 21902468
Sci Rep. 2016 Dec 12;6:38541
pubmed: 27941871
Theranostics. 2019 Oct 14;9(25):7680-7696
pubmed: 31695794
Biomaterials. 2019 Dec;223:119475
pubmed: 31520888
Cancer Biomark. 2016 Mar 25;17(2):125-32
pubmed: 27062568
Trends Mol Med. 2015 Oct;21(10):595-608
pubmed: 26432017
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9066-E9075
pubmed: 29073103
Biomaterials. 2017 Mar;121:121-129
pubmed: 28086180
Oncogene. 2019 Jun;38(26):5158-5173
pubmed: 30872795
Int J Cancer. 2020 Feb 15;146(4):1052-1063
pubmed: 31259424
Colloids Surf B Biointerfaces. 2018 Nov 1;171:391-397
pubmed: 30064087
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756922
PLoS One. 2016 Mar 23;11(3):e0152213
pubmed: 27006994
J Nanobiotechnology. 2019 Jul 18;17(1):85
pubmed: 31319859
Breast Cancer Res Treat. 2019 Nov;178(1):57-62
pubmed: 31346846
Mol Cancer Ther. 2005 Oct;4(10):1595-604
pubmed: 16227410
Oncogene. 2019 Jul;38(28):5740-5741
pubmed: 31068668
J Biol Chem. 2016 Dec 23;291(52):26589-26597
pubmed: 27852825
Cancer Radiother. 2016 Sep;20 Suppl:S139-46
pubmed: 27522187
Chem Sci. 2018 Nov 27;10(5):1555-1561
pubmed: 30809374
J Exp Clin Cancer Res. 2019 Apr 16;38(1):166
pubmed: 30992025
Cancer Res. 2003 Aug 1;63(15):4331-7
pubmed: 12907600
J Exp Clin Cancer Res. 2019 Jul 19;38(1):320
pubmed: 31324203
J Biol Chem. 2012 May 4;287(19):15874-85
pubmed: 22396543
J Hematol Oncol. 2018 Dec 12;11(1):136
pubmed: 30541578
Am Soc Clin Oncol Educ Book. 2016;35:298-308
pubmed: 27249709
Nucleic Acids Res. 2019 Jan 8;47(D1):D89-D93
pubmed: 30335161
Nat Commun. 2019 Sep 25;10(1):4355
pubmed: 31554797
Cell Mol Bioeng. 2016 Dec;9(4):509-529
pubmed: 28392840
Med Sci Monit. 2019 Mar 26;25:2211-2220
pubmed: 30910994
Biomedicine (Taipei). 2017 Dec;7(4):23
pubmed: 29130448
Oncotarget. 2015 Dec 29;6(42):44179-90
pubmed: 26496034
Oncotarget. 2015 Aug 14;6(23):19514-27
pubmed: 26098775
Mol Cell Biochem. 2019 Dec;462(1-2):97-105
pubmed: 31473882
Biochem Biophys Rep. 2019 Nov 27;21:100713
pubmed: 31828227
Small. 2019 Nov;15(47):e1903761
pubmed: 31614072
Theranostics. 2017 Jan 26;7(3):789-804
pubmed: 28255367
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41
pubmed: 21873242
Leukemia. 2009 Sep;23(9):1643-9
pubmed: 19369960
Oncogene. 2018 Nov;37(47):6105-6118
pubmed: 29991801
J Mol Biol. 2016 Feb 22;428(4):688-692
pubmed: 26434508
J Clin Invest. 2015 Sep;125(9):3335-7
pubmed: 26325031
Acta Biomater. 2020 Jan 1;101:519-530
pubmed: 31629893
Emerg Med Clin North Am. 2014 Feb;32(1):167-203
pubmed: 24275174
Semin Cancer Biol. 2017 Jun;44:170-181
pubmed: 28215970
Mol Ther. 2020 Mar 4;28(3):975-985
pubmed: 31911034
Mol Ther. 2016 Oct;24(10):1836-1847
pubmed: 27506293
Biotechnol Bioeng. 2000 May 5;68(3):328-38
pubmed: 10745201
Sheng Wu Gong Cheng Xue Bao. 2019 Aug 25;35(8):1537-1545
pubmed: 31441625

Auteurs

Mahendran Chinnappan (M)

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Akhil Srivastava (A)

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Narsireddy Amreddy (N)

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Mohammad Razaq (M)

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Vipul Pareek (V)

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Rebaz Ahmed (R)

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Graduate Program in Biomedical Sciences, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Meghna Mehta (M)

Department of Radiation Oncology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Jo Elle Peterson (JE)

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Anupama Munshi (A)

Department of Radiation Oncology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Rajagopal Ramesh (R)

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Graduate Program in Biomedical Sciences, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Electronic address: rajagopal-ramesh@ouhsc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Cellules › Structures cellulaires › Espace intracellulaire › Cytoplasme › Structures cytoplasmiques › Organites › Vésicules cytoplasmiques › Vésicules de transport › Exosomes › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Tumeurs › Exosomes as drug delivery vehicle and...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Véhicules pharmaceutiques › Exosomes as drug delivery vehicle and...